PDS Biotechnology jumps on Q3 results, positive cancer drug trial data

PDS Biotechnology

14/11/2022 17:50

** Cancer therapy developer PDS Biotechnology Corp's
 PDSB.O  shares jump 27% to $7, an 11-month high
    ** Company reports Q3 adj net loss of $0.26/shr vs est loss
of $0.28/shr - Refinitiv
    ** PDSB says data from mid-stage clinical trial of
IMMUNOCERV, a drug treating cervical cancer, shows greater than
60% shrinkage of tumors among all patients tested 
    ** More than 1 mln shares traded, 36.7x 25-day moving avg
    ** All 8 brokerages rate stock "buy" or higher; median PT
$15.50
    ** Stock down 9.4% vs 28% decline in Nasdaq Composite index
 .IXIC 
 (Reporting by Johann M Cherian in Bengaluru)
 ((johann.mcherian@thomsonreuters.com))